How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 301–400 of 1,000
The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines
Swinney, D. C. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113501199 · Cited by 71
Self-citationMartinez, N. J., Titus, S. A., Wagner, A. K., & Simeonov, A. M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1091814 · Cited by 75
Andreoli, F., Barbosa, A. J. M., Parenti, M. D., & Río, A. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581918 · Cited by 68
Park, J., Koh, M., Koo, J. Y., Lee, S., & Park, S. B. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00671 · Cited by 71
Cornaglia, M., Lehnert, T., & Gijs, M. A. M. (2017) · Lab on a Chip · doi:10.1039/c7lc00509a · Cited by 68
Brownjohn, P. W., Smith, J., Portelius, E., Serneels, L., Kvartsberg, H., De Strooper, B., Blennow, K., Zetterberg, H., & Livesey, F. J. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.006 · Cited by 65
High-throughput screening for modulators of cellular contractile force
Park, C. Y., Zhou, E. H., Tambe, D. T., Chen, B., Lavoie, T. L., Dowell, M. L., Simeonov, A. M., Maloney, D. J., Marinković, А., Tschumperlin, D. J., et al. (2015) · Integrative Biology · doi:10.1039/c5ib00054h · Cited by 73
Comess, K. M., McLoughlin, S. M., Oyer, J. A., Richardson, P. L., Stöckmann, H., Vasudevan, A., & Warder, S. E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01921 · Cited by 71
Nanomaterials for Biosensors and Implantable Biodevices
Luz, R. A. S., Iost, R. M., & Crespilho, F. N. (2012) · Springer eBooks · doi:10.1007/978-3-642-29250-7_2 · Cited by 79
A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules
Lee, H. W., Khan, S. Q., Faridi, M. H., Wei, C., Tardi, N. J., Altintas, M. M., Elshabrawy, H. A., Mangos, S., Quick, K. L., Sever, S., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090859 · Cited by 72
Al-Ali, H., Lee, D.-H., Danzi, M. C., Nassif, H., Gautam, P., Wennerberg, K., Zuercher, B., Drewry, D. H., Lee, J. K., Lemmon, V. P., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00289 · Cited by 66
The development of high-content screening (HCS) technology and its importance to drug discovery
Fraietta, I., & Gasparri, F. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1165203 · Cited by 76
Access to a Structurally Complex Compound Collection via Ring Distortion of the Alkaloid Sinomenine
Garcia, A., Drown, B., & Hergenrother, P. J. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b02333 · Cited by 66
Cheminformatics Tools for Analyzing and Designing Optimized Small Molecule Collections and Libraries
Moret, N., Clark, N. A., Hafner, M. A., Wang, Y., Lounkine, E., Medvedovic, M., Wang, J., Gray, N. S., Jenkins, J. L., & Sorger, P. K. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.018 · Cited by 74
Emerging drug development technologies targeting ubiquitination for cancer therapeutics
Veggiani, G., Gerpe, M. C. R., Sidhu, S. S., & Zhang, W. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.003 · Cited by 63
The translational challenge in Chagas disease drug development
Kratz, J. M., Gonçalves, K. R., Romera, L. M. D., Moraes, C. B., Bittencourt-Cunha, P. R., Schenkman, S., Chatelain, E., & Sosa‐Estáni, S. (2022) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760200501 · Cited by 66
Antitumor activity of an anti‐ CD 98 antibody
Hayes, G. M., Chinn, L., Cantor, J. M., Cairns, B., Levashova, Z. B., Tran, H., Velilla, T., Duey, D. Y., Lippincott, J., Zachwieja, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29415 · Cited by 64
Krasavin, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.028 · Cited by 70
HDAC inhibitors in kidney development and disease
Brilli, L. L., Swanhart, L. M., de Caestecker, M. P., & Hukriede, N. A. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2320-8 · Cited by 66
Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
Kithcart, A. P., & MacRae, C. A. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.01.004 · Cited by 77
Riggs, J. R., Nagy, M. A., Elsner, J., Erdman, P. E., Cashion, D., Robinson, D., Harris, R., Huang, D., Tehrani, L. R., Deyanat‐Yazdi, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01223 · Cited by 65
Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M., & Bredt, D. S. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.001 · Cited by 64
Saikin, S. K., Kreisbeck, C., Sheberla, D., Becker, J. S., & Aspuru-Guzik, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546690 · Cited by 63
STarFish: A Stacked Ensemble Target Fishing Approach and its Application to Natural Products
Cockroft, N. T., Cheng, X., & Fuchs, J. R. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00489 · Cited by 69
Human Organoids for the Study of Retinal Development and Disease
Bell, C. M., Zack, D. J., & Berlinicke, C. A. (2020) · Annual Review of Vision Science · doi:10.1146/annurev-vision-121219-081855 · Cited by 71
Established and Emerging Trends in Computational Drug Discovery in the Structural Genomics Era
Taboureau, O., Baell, J. B., Fernández‐Recio, J., & Villoutreix, B. O. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.007 · Cited by 69
Cheeseman, M. D., Chessum, N. E. A., Rye, C. S., Pasqua, E., Tucker, M. J., Wilding, B., Evans, L. E., Lepri, S., Richards, M., Sharp, S. Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01055 · Cited by 66
High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need
Hughes, R. E., Elliott, R. J. R., Dawson, J. C., & Carragher, N. O. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.02.015 · Cited by 62
Vacuolin‐1 inhibits autophagy by impairing lysosomal maturation via PIK fyve inhibition
Sano, O., Kazetani, K., Funata, M., Fukuda, Y., Matsui, J., & Iwata, H. (2016) · FEBS Letters · doi:10.1002/1873-3468.12195 · Cited by 63
Oronsky, B. T., Paulmurugan, R., Foygel, K., Scicinski, J. J., Knox, S. J., Peehl, D. M., Zhao, H., Ning, S., Cabrales, P., Summers, T. A., et al. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1268600 · Cited by 62
Anti-GiardiaDrug Discovery: Current Status and Gut Feelings
Riches, A. G., Hart, C. J. S., Trenholme, K. R., & Skinner‐Adams, T. S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00910 · Cited by 65
Important challenges to finding new leads for new antibiotics
Farha, M. A., Tu, M. M., & Brown, E. D. (2024) · Current Opinion in Microbiology · doi:10.1016/j.mib.2024.102562 · Cited by 78
Flow Cytometry: Impact on Early Drug Discovery
Edwards, B. S., & Sklar, L. A. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115578273 · Cited by 66
Computational methods for prediction of in vitro effects of new chemical structures
Banerjee, P., Siramshetty, V. B., Drwal, M. N., & Preissner, R. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0162-2 · Cited by 60
Lapinsky, D. J., & Johnson, D. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.136 · Cited by 60
Chemoproteomic-enabled phenotypic screening
Conway, L. P., Li, W., & Parker, C. G. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.012 · Cited by 63
An overview of metal-free synthetic routes to isoxazoles: the privileged scaffold
Das, S., & Chanda, K. (2021) · RSC Advances · doi:10.1039/d1ra04624a · Cited by 64
Developing nociceptor-selective treatments for acute and chronic pain
Jayakar, S. S., Shim, J., Jo, S., Bean, B. P., Singeç, I., & Woolf, C. J. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9837 · Cited by 63
Drug repurposing through nonhypothesis driven phenotypic screening
Reaume, A. G. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.09.007 · Cited by 61
Long, T., Neitz, R. J., Beasley, R., Kalyanaraman, C., Suzuki, B. M., Jacobson, M. P., Dissous, C., McKerrow, J. H., Drewry, D. H., Zuercher, W. J., et al. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004356 · Cited by 65
Becher, I., Dittmann, A., Savitski, M. M., Hopf, C., Drewes, G., & Bantscheff, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500235n · Cited by 60
Vempati, U. D., Przydzial, M. J., Chung, C., Abeyruwan, S., Mir, A., Sakurai, K., Visser, U., Lemmon, V. P., & Schürer, S. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049198 · Cited by 59
Löscher, W., & Klein, P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107934 · Cited by 58
AI-Powered Microfluidics: Shaping the Future of Phenotypic Drug Discovery
Liu, J., Du, H., Huang, L., Xie, W., Liu, K., Zhang, X., Chen, S., Zhang, Y., Li, D., & Pan, H. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c07665 · Cited by 75
Repurposing Drugs to Target the Diabetes Epidemic
Turner, N. A., Zeng, X., Osborne, B., Rogers, S., & Ye, J.-M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.007 · Cited by 62
Utilizing Zebrafish Visual Behaviors in Drug Screening for Retinal Degeneration
Ganzen, L. C., Venkatraman, P., Pang, C. P., Leung, Y. F., & Zhang, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061185 · Cited by 63
Jordi, J., Guggiana-Nilo, D., Bolton, A. D., Prabha, S., Ballotti, K., Herrera, K. J., Rennekamp, A. J., Peterson, R. T., Lutz, T. A., & Engert, F. (2018) · Science Advances · doi:10.1126/sciadv.aav1966 · Cited by 73
Systematic Chemogenetic Library Assembly
Canham, S. M., Wang, Y., Cornett, A., Auld, D. S., Baeschlin, D. K., Patoor, M., Skaanderup, P. R., Honda, A., Llamas, L., Wendel, G., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.004 · Cited by 62
Drugs/agents for the treatment of ischemic stroke: Advances and perspectives
Jia, J., Jiao, W., Wang, G., Wu, J., Huang, Z., & Zhang, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.22009 · Cited by 64
Deep learning large-scale drug discovery and repurposing
Yu, M., Li, W., Yu, Y., Zhao, Y., Xiao, L., Lauschke, V. M., Cheng, Y.-Y., Zhang, X., & Wáng, Y. (2024) · Nature Computational Science · doi:10.1038/s43588-024-00679-4 · Cited by 68
The development of label-free cellular assays for drug discovery
Ye, F. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.642360 · Cited by 60
Serrill, J., Wan, X., Hau, A. M., Jang, H. S., Coleman, D. J., Indra, A. K., Alani, A. W. G., McPhail, K. L., & Ishmael, J. E. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0303-x · Cited by 58
dos Santos, B. S., da Silva, L. C. N., da Silva, T. D., Rodrigues, J. F. S., Grisotto, M. A. G., Correia, M. T. D. S., Napoleão, T. H., da Silva, M. V., & Paiva, P. M. G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01466 · Cited by 67
Timelines of translational science: From technology initiation to FDA approval
McNamee, L. M., Walsh, M. J., & Ledley, F. D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177371 · Cited by 54
Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies
Vincent, F., Loria, P. M., Weston, A. D., Steppan, C. M., Doyonnas, R., Wang, Y., Rockwell, K. L., & Peakman, M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.08.009 · Cited by 64
Jin, J., Wu, Y., Zhao, Z., Wu, Y., Zhou, Y.-D., Liu, S., Sun, Q., Yang, G., Lin, J., Nagle, D. G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160606 · Cited by 57
“Apart from the lengthy target-based drug discovery (TDD) design process, this method is envisioned as a feasible way to accelerate the development of a STAT3 degrader through a more phenotypic drug discovery (PDD) strategy (27, 28).”
Kidney failure: aims for the next 10 years and barriers to success
Remuzzi, G., Benigni, A., Finkelstein, F. O., Grünfeld, J., Joly, D. A., Katz, I. J., Liu, Z.-H., Miyata, T., Perico, N., Rodríguez‐Iturbe, B., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60438-9 · Cited by 61
Balancing novelty with confined chemical space in modern drug discovery
Medina‐Franco, J. L., Martínez‐Mayorga, K., & Meurice, N. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.872624 · Cited by 58
Unconventional screening approaches for antibiotic discovery
Farha, M. A., & Brown, E. D. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12803 · Cited by 60
Tosh, D. K., Finley, A., Paoletta, S., Moss, S. M., Gao, Z., Gizewski, E. T., Auchampach, J. A., Salvemini, D., & Jacobson, K. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501021n · Cited by 56
Wong, S. S. W., Samaranayake, L. P., & Seneviratne, C. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.009 · Cited by 64
High Throughput and Computational Repurposing for Neglected Diseases
Hernandez, H., Soeung, M., Zorn, K. M., Ashoura, N. E., Mottin, M., Andrade, C. H., Caffrey, C. R., Siqueira-Neto, J. L., & Ekins, S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2558-3 · Cited by 61
Anticancer metallohelices: nanomolar potency and high selectivity
Kaner, R. A., Allison, S. J., Faulkner, A. D., Phillips, R. M., Roper, D. I., Shepherd, S. L., Simpson, D. H., Waterfield, N. R., & Scott, P. (2015) · Chemical Science · doi:10.1039/c5sc03677a · Cited by 60
Kim, J., Jung, J., Koo, J., Cho, W., Lee, W. S., Kim, C., Park, W., & Park, S. B. (2016) · Nature Communications · doi:10.1038/ncomms13196 · Cited by 59
Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges
Gubič, Š., Hendrickx, L. A., Toplak, Ž., Sterle, M., Peigneur, S., Tomašič, T., Pardo, L. A., Tytgat, J., Zega, A., & Mašič, L. P. (2021) · Medicinal Research Reviews · doi:10.1002/med.21800 · Cited by 61
Sawada, R., Iwata, M., Tabei, Y., Yamato, H., & Yamanishi, Y. (2018) · Scientific Reports · doi:10.1038/s41598-017-18315-9 · Cited by 58
Wilkinson, I. V. L., Perkins, K. J., Dugdale, H. F., Moir, L., Vuorinen, A., Chatzopoulou, M., Squire, S. E., Monecke, S., Lomow, A., Geese, M., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201912392 · Cited by 60
Bakshi, H. A., Zoubi, M. S. A., Hakkim, F. L., Aljabali, A. A. A., Rabi, F., Hafiz, A. A., Al‐Batayneh, K., Al‐Trad, B., Ansari, P., Nasef, M. M., et al. (2020) · Nutrients · doi:10.3390/nu12061901 · Cited by 54
Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery
Jung, H. J., & Kwon, H. J. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0618-3 · Cited by 60
Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Badria, F. A.-E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83082 · Cited by 66
Epigenetic control of gene function in schistosomes: a source of therapeutic targets?
Cabezas‐Cruz, A., Lancelot, J., Caby, S., Oliveira, G., & Pierce, R. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00317 · Cited by 56
Cho, H.-J., Ahn, K.-C., Choi, J. Y., Hwang, S., Kim, W., Um, H., & Park, J. K. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2831 · Cited by 53
Berg, E. L., Hsu, Y.-C., & Lee, J. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.013 · Cited by 66
Discovery and optimization of novel dual dithiocarbamates as potent anticancer agents
Li, R., Wang, H., Li, Y., Wang, Z., Wang, X., Wang, Y., Ge, Z., & Li, R. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.02.030 · Cited by 53
Patel, D. A., Patel, A. C., Nolan, W. C., Zhang, Y., & Holtzman, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036594 · Cited by 59
Behavioral Analysis of Dopaminergic Activation in Zebrafish and Rats Reveals Similar Phenotypes
Ek, F., Malo, M., Andersson, M. Å., Wedding, C., Kronborg, J., Svensson, P., Waters, N., Petersson, P., & Olsson, R. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00014 · Cited by 65
Orally Active Epoxyeicosatrienoic Acid Analogs
Campbell, W. B., Imig, J. D., Schmitz, J. M., & Falck, J. R. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000523 · Cited by 54
Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome
Griffin, A., Jaishankar, P., Grandjean, J.-M. M., Olson, S. H., Renslo, A. R., & Baraban, S. C. (2019) · Brain Communications · doi:10.1093/braincomms/fcz008 · Cited by 56
Chemoproteomics, A Broad Avenue to Target Deconvolution
Gao, Y., Ma, M., Li, W., & Lei, X. (2023) · Advanced Science · doi:10.1002/advs.202305608 · Cited by 60
Cottrell, J. R., Levenson, J. M., Kim, S. H., Gibson, H. E., Richardson, K. A., Sivula, M., Li, B., Ashford, C. J., Heindl, K. A., Babcock, R. J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5362-12.2013 · Cited by 58
Sandercock, A. M., Rust, S., Guillard, S., Sachsenmeier, K. F., Holoweckyj, N., Hay, C., Flynn, M., Huang, Q., Yan, K., Herpers, B., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0415-0 · Cited by 53
Rust, S., Guillard, S., Sachsenmeier, K., Hay, C., Davidson, M., Karlsson, A., Karlsson, R., Brand, E., Lowne, D., Elvin, J., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-11 · Cited by 51
Suzawa, M., Miranda, D. A., Ramos, K. A., Ang, K. K.-H., Faivre, E. J., Wilson, C. G. M., Caboni, L., Arkin, M. R., Kim, Y.-S., Fletterick, R. J., et al. (2015) · eLife · doi:10.7554/elife.09003 · Cited by 52
White, D. T., Eroglu, A. U., Wang, G., Zhang, L., Sengupta, S., Ding, D., Rajpurohit, S. K., Walker, S. L., Ji, H., Qian, J. X., et al. (2016) · Nature Protocols · doi:10.1038/nprot.2016.142 · Cited by 53
Cell and small animal models for phenotypic drug discovery
Szabo, M., Akusjärvi, S. S., Saxena, A., Liu, J., Chandrasekar, G., & Kitambi, S. S. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s129447 · Cited by 53
Assay Guidance Manual : Quantitative Biology and Pharmacology in Preclinical Drug Discovery
Coussens, N. P., Sittampalam, G. S., Guha, R., Brimacombe, K. R., Grossman, A., Chung, T. D. Y., Weidner, J. R., Riss, T., Trask, O. J., Auld, D. S., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12570 · Cited by 52
Artificial intelligence for high content imaging in drug discovery
Puigvert, J. C., & Spjuth, O. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102842 · Cited by 57
Fauzi, F. M., Koutsoukas, A., Lowe, R., Joshi, K., Fan, T., Glen, R. C., & Bender, A. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci3005513 · Cited by 51
Deciphering the Cellular Targets of Bioactive Compounds Using a Chloroalkane Capture Tag
Ohana, R. F., Kirkland, T. A., Woodroofe, C. C., Levin, S., Uyeda, H. T., Otto, P., Hurst, R., Robers, M. B., Zimmerman, K., Encell, L. P., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00351 · Cited by 55
Gallardo, V. E., Varshney, G. K., Lee, M., Bupp, S., Xu, L., Shinn, P., Crawford, N. P. S., Inglese, J., & Burgess, S. M. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018689 · Cited by 51
Recycling side-effects into clinical markers for drug repositioning
Duran‐Frigola, M., & Aloy, P. (2012) · Genome Medicine · doi:10.1186/gm302 · Cited by 53
Structure and Function of Prokaryotic UDP-Glucose Pyrophosphorylase, A Drug Target Candidate
Berbis, M. A., Sánchez-Puelles, J.-M., Cañada, F. J., & Jiménez‐Barbero, J. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150114151248 · Cited by 53
Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery
Figuera-Losada, M., Rojas, C., & Slusher, B. S. (2014) · SLAS Discovery · doi:10.1177/1087057113499406 · Cited by 49
Current and Future Chemotherapy for Chagas Disease
Gaspar, L., Moraes, C. B., Freitas-Junior, L. H., Ferrari, S., Costantino, L., Costi, M. P., Coron, R. P., Smith, T., Siqueira-Neto, J. L., McKerrow, J. H., et al. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666151015120804 · Cited by 52
Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines
Belle, K. V., Herman, J., Boon, L., Waer, M., Sprangers, B., & Louat, T. (2016) · Journal of Immunology Research · doi:10.1155/2016/5281823 · Cited by 63
Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research
Turnbull, M. T., Zubair, A. C., Meschia, J. F., & Freeman, W. D. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0073-8 · Cited by 55
Molecular mechanism matters: Benefits of mechanistic computational models for drug development
Clegg, L. E., & Mac Gabhann, F. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.002 · Cited by 50
In silico assessment of adverse drug reactions and associated mechanisms
Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.018 · Cited by 49
Ochiana, S. O., Pandarinath, V., Wang, Z., Kapoor, R., Ondrechen, M. J., Ruben, L., & Pollastri, M. P. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.038 · Cited by 49
Considerations for designing chemical screening strategies in plant biology
Serrano, M., Kombrink, E., & Meesters, C. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00131 · Cited by 60
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.